Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-27
2007-11-27
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S260100, C544S278000, C544S239000
Reexamination Certificate
active
10544069
ABSTRACT:
The present invention provides a compound represented by the formula:wherein R1is a C1-4alkyl; R2is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C1-4alkyl and (4′) a C1-4alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a C1-4alkoxy-C1-4alkyl, (3′) a mono-C1-4alkyl-carbamoyl-C1-4alkyl, (4′) a C1-4alkoxy and (5′) a mono-C1-4alkylcarbamoyl-C1-4alkoxy, or the like; R3is a C1-4alkyl; R4is a C1-4alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
REFERENCES:
patent: 6048863 (2000-04-01), Furuya et al.
patent: 6297379 (2001-10-01), Furuya et al.
patent: 6340686 (2002-01-01), Furuya et al.
patent: 2003/0004172 (2003-01-01), Harter et al.
patent: 2003/0055269 (2003-03-01), Fukuoka et al.
patent: 2003/0134863 (2003-07-01), Furuya et al.
patent: 2004/0023987 (2004-02-01), Hata et al.
patent: 2004/0034039 (2004-02-01), Nakano et al.
patent: 1297850 (2003-04-01), None
patent: WO 00/56739 (2000-09-01), None
patent: WO 02/43766 (2002-06-01), None
patent: WO 02/47722 (2002-06-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 03/064429 (2003-08-01), None
patent: WO 03/075958 (2003-09-01), None
patent: WO 03/086464 (2003-10-01), None
Jones et al, “British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.” Gut 2000, (Suppl II)47:ii1-ii19.
T. Hara, et al., “Suppression of a Pituitary-Ovarian Axis by Chronic Oral Administration of a Novel Nonpeptide Gonadotropin-Releasing Hormone Antagonist, TAK-013, in Cynomolgus Monkeys”, The Journal of Clinical Endocrinology & Metabolism, (2003), pp. 1697-1704, vol. 88, No. 4.
S. Sasaki, et al., “Discovery of a Thieno[2,3-d]pyrimidine-2,4-dione Bearing a p-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non-Peptide Antagonist for the Human Luteinizing Hormone-Releasing Hormone Receptor”, J. Med. Chem., (2003), pp. 113-124, vol. 46.
Z. Guo, et al., “Synthesis and Structure—Activity Relationships of Thieno[2,3-d]pyrimidine-2,4-dione Derivatives as Potent GnRH Receptor Antagonists”, Bioorganic & Medicinal Chemistry Letters, (2003), pp. 3617-3622, vol. 13.
Cho Nobuo
Hitaka Takenori
Imada Takashi
Kusaka Masami
Miwa Kazuhiro
Coleman Brenda L.
Conlin David G.
Edwards Angell Palmer & & Dodge LLP
Moore Susanna
Takeda Pharmaceutical Company
LandOfFree
Thienopyrimidine compounds and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienopyrimidine compounds and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyrimidine compounds and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819066